Facing the HIV epidemic can feel overwhelming, but there's good news: the World Health Organization (WHO) has just released updated recommendations on HIV clinical management, offering hope and guidance for a healthier future. These new guidelines are packed with the latest evidence-based strategies, aiming to improve treatment outcomes, reduce HIV-related deaths, and accelerate our progress toward ending AIDS as a public health threat.
These updated recommendations, building on the previous ones from 2021, reflect significant advancements in HIV treatment. They provide updated guidance on antiretroviral therapy, managing the transmission of HIV from mother to child (vertical transmission), and preventing tuberculosis (TB) in people living with HIV.
Optimizing Antiretroviral Therapy:
The updated guidelines strongly recommend dolutegravir-based regimens as the preferred choice for both initial and subsequent HIV treatment. This is a significant step forward. For those whose treatment isn't working, the guidelines now recommend darunavir/ritonavir as the preferred option when a protease inhibitor (PI) is needed, replacing earlier preferences. The guidelines also support reusing tenofovir and abacavir in later treatments, thanks to better outcomes, practical benefits, and potential cost savings. Moreover, long-acting injectable antiretroviral therapy is recommended in specific cases, such as for adults and adolescents who struggle with daily oral medications. Oral two-drug regimens are also suggested as simpler treatment options for certain stable individuals.
Strengthening Prevention of Vertical HIV Transmission:
Despite remarkable progress in preventing mother-to-child transmission, new infections still occur, especially during breastfeeding. The updated guidelines emphasize a person-centered, public health approach that prioritizes maternal choice and infant well-being.
WHO continues to recommend that mothers with HIV exclusively breastfeed for the first six months, continuing up to 12 months, and possibly up to 24 months or longer, alongside effective maternal antiretroviral therapy and proper complementary feeding. All HIV-exposed infants should receive six weeks of postnatal prophylaxis, ideally with nevirapine, while those at higher risk should receive enhanced triple-drug prophylaxis. Extended infant prophylaxis may be used until the mother's viral load is suppressed or breastfeeding has stopped.
Prioritizing TB Prevention in People Living with HIV:
Tuberculosis remains a leading cause of death among people living with HIV. To improve the use and completion of TB preventive therapy, WHO now recommends three months of weekly isoniazid plus rifapentine (3HP) as the preferred TB preventive treatment for adults and adolescents with HIV. Other WHO-recommended regimens remain available based on clinical and programmatic considerations. These interventions will help integrate services better, aiming to reduce TB-related deaths in people with HIV while simplifying how care is delivered.
Supporting Countries to Accelerate Impact:
“These updated recommendations reflect WHO’s commitment to ensuring that people living with HIV benefit from the most effective, safe and practical treatment options available,” said Dr. Tereza Kasaeva, Director, Department of HIV, TB, viral Hepatitis and STIs of WHO Headquarters in Geneva. “By simplifying treatment, improving adherence and addressing persistent gaps in prevention, they will help countries strengthen HIV programmes and save lives.”
These recommendations will be included in the next edition of the WHO consolidated HIV guidelines and are designed to inform national HIV programs, clinicians, partners, and communities worldwide.
But here's where it gets controversial... The shift in preferred treatment options and the emphasis on breastfeeding might spark debate. What do you think about the balance between maternal choice and infant health? Do you agree with the new recommendations, or do you have alternative perspectives? Share your thoughts in the comments below!
